Health

Myeloma: CAR T-Cell Therapy Produces Deep and Durable Responses

0
Myeloma: CAR T-Cell Therapy Produces Deep and Durable Responses

(MedPage Today) — A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and durable responses in patients with heavily pretreated…
Read More

admin

Clinical Challenges: Essential Thrombocythemia

Previous article

Op-Ed: Are We Shooting Ourselves in the Foot?

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Health